Skip to main content

Branded

  • National Consumers League survey finds 1-in-5 adults never received a flu shot

    WASHINGTON — A survey released by the National Consumers League found that more than 1-in-5 (22%) U.S. parents surveyed admitted they’ve never received a flu shot, and only half (53%) of parents with children ages 17 years and younger have received a flu vaccination within the last year. 

  • NCPA: Preferred pharmacy networks don't necessarily net prescription savings

    ALEXANDRIA, Va. — The Medicare Part D program and taxpayers often pay more when prescription drugs are obtained through "preferred" pharmacies and mail order than they would if the same prescriptions were filled through other, "non-preferred" pharmacies, according to a cost comparison made by the National Community Pharmacists Association released Thursday using the Medicare Plan Finder website. The findings come shortly after recently proposed requirements that officials with the U.S.

  • Par Pharmaceutical to distribute authorized generic of Covis's Lanoxin (digoxin) tablets

    WOODCLIFF LAKE, N.J. — Par Pharmaceutical on Thursday announced that it has entered into an exclusive U.S. supply and distribution agreement with Covis Pharma S.a.r.l. to distribute the authorized generic version of Covis's Lanoxin (digoxin) tablets. 

    According to IMS Health data, annual U.S. sales of digoxin tablets are approximately $44 million. 

  • CHPA responds to Food and Drug Administration’s APAP recommendation

    WASHINGTON — The Consumer Healthcare Products Association on Thursday responded to the Food and Drug Administration’s recommendation to discontinue prescribing and dispensing prescription combination medicines that contain more than 325 mg of acetaminophen per dosage unit, suggesting it would not impact use of over-the-counter formulations containing acetaminophen.

  • Nuvo Research's Pennsaid 2% approved to treat pain associated with osteoarthritis of the knee

    MISSISSAUGA, Ontario — Nuvo Research on Friday announced that the U.S. Food and Drug Administration approved Mallinckrodt's new drug application for Pennsaid (diclofenac sodium topical solution) 2%.

  • Easton Pharmaceuticals seeking investment in medical marijuana industry

    TORONTO — Easton Pharmaceuticals on Thursday announced it is speeding up negotiations with an Ontario-based company toward forming a possible investment/partnership toward their medical marijuana initiatives, which includes participating in their government application for both a growers and distributorship license in Canada and other possible international initiatives. 

  • Analysis: Only 1-in-3 adults ages 18 to 64 years get the flu shot

    WASHINGTON — An analysis released Tuesday by the Trust for America's Health found that only 35.7% of adults ages 18 to 64 years got the flu shot last season. By comparison, 56.6% of children ages 6 months to 17 years old and 66.2% of seniors were vaccinated.  

    "The trend of low vaccination rates among younger adults is particularly troubling this year, when they are more at risk than usual for the effects of the H1N1 strain of flu that's circulating," stated Jeffrey Levi, executive director of TFAH.

  • FDA advisory panel recommends approval of Merck's vorapaxar

    WHITEHOUSE STATION, N.J. — Merck on Wednesday commended the U.S. Food and Drug Administration’s Cardiovascular and Renal Drugs Advisory Committee’s recommendation for approval of vorapaxar. Vorapaxar is the company’s investigational antiplatelet medicine for the reduction of atherothrombotic events, when added to standard of care, in patients with a history of heart attack and no history of stroke or transient ischemic attack.

X
This ad will auto-close in 10 seconds